Fig. 3: Efficacy among patients with R/R SCLC. | Nature Medicine

Fig. 3: Efficacy among patients with R/R SCLC.

From: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Fig. 3: Efficacy among patients with R/R SCLC.The alternative text for this image may have been generated using AI.

a, Primary endpoint of DOR by dose for the part 2a dose-optimization cohorts. b, Exploratory endpoints of PFS by dose for the part 2a dose-optimization cohorts. c, OS by dose for the part 2a dose-optimization cohorts of 1.8 mg kg−1 and 2.5 mg kg−1. NR, not reached.

Back to article page